(Q36828128)

16 August 2017

1 reference

title

Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management (English)

1 reference

16 August 2017

1 reference

5

Steven E Lipshultz

1 reference

16 August 2017

Elly Barry

1

1 reference

16 August 2017

Jorge A Alvarez

series ordinal

2

1 reference

16 August 2017

Rebecca E Scully

series ordinal

3

1 reference

16 August 2017

Tracie L Miller

series ordinal

4

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

Expert Opinion on Pharmacotherapy

16 August 2017

published in

1 reference

16 August 2017

volume

8

1 reference

16 August 2017

issue

8

1 reference

16 August 2017

page(s)

1039-1058

1 reference

Adriamycin. A new anticancer drug with significant clinical activity

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Long-term effects of treatments for childhood cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Chronic health conditions in adult survivors of childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

A clinicopathologic analysis of adriamycin cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Long-term follow-up of childhood cancer survivors: future directions for clinical care and research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Long-term follow-up of pediatric cancer survivors: education, surveillance, and screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Models of care for survivors of childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Barriers to follow-up care of survivors in the United States and the United Kingdom.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Importance of clinical and epidemiological research in defining the long-term clinical care of pediatric cancer survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Delivering long-term follow-up care to pediatric cancer survivors: transitional care issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Acute arrhythmogenicity of doxorubicin administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Cardiovascular toxicity with cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Anthracycline-induced cardiotoxicity in children and young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

The cardiotoxicity of adriamycin and daunomycin in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Cardiac toxicity 4 to 20 years after completing anthracycline therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Predicting drug response and toxicity based on gene polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Cardiotoxicity of cancer chemotherapy: implications for children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Pathology of radiation and anthracycline cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Trends in prevalence and outcome of heart failure with preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Outcome of heart failure with preserved ejection fraction in a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Molecular basis of anthracycline-induced cardiotoxicity and its prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Cardiotoxicity of cytotoxic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Doxorubicin-induced cardiac mitochondrionopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Time-Dependent and Tissue-Specific Accumulation of mtDNA and Respiratory Chain Defects in Chronic Doxorubicin Cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Trastuzumab-associated cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Role of neuregulin-1/ErbB2 signaling in endothelium-cardiomyocyte cross-talk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Stress pathways and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

The effectiveness of the anthracycline analog 4'-epidoxorubicin in the treatment of experimental tumors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Mitoxantrone: a new anticancer drug with significant clinical activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

A comparison of mitoxantrone and doxorubicin in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

A pharmacoeconomic evaluation of the use of dexrazoxane in preventing anthracycline-induced cardiotoxicity in patients with stage IIIB or IV metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Antioxidant nutrients and adriamycin toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Serum cardiac troponin and subclinical cardiac status in pediatric chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Comparison of N-terminal pro-B-type natriuretic peptide levels in critically ill children with sepsis versus acute left ventricular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

International Society for Heart and Lung Transplantation: Practice guidelines for management of heart failure in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Angiotensin-converting enzyme inhibitor therapy for ventricular dysfunction in infants, children and adolescents: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Role of afterload reduction in the prevention of late anthracycline cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Carvedilol in children with cardiomyopathy: 3-year experience at a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Carvedilol as therapy in pediatric heart failure: an initial multicenter experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Intermediate effects of treatment with metoprolol or carvedilol in children with left ventricular systolic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Protective effects of carvedilol against anthracycline-induced cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Angiotensin inhibition in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Prevention of adriamycin-induced cardiotoxicity by prenylamine: a pilot double blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Cardiac changes associated with growth hormone therapy among children treated with anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Healthy lifestyle factors in the primary prevention of coronary heart disease among men: benefits among users and nonusers of lipid-lowering and antihypertensive medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Gu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.8.1039

10.1517/14656566.8.8.1039

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference